FCM
APGE

Farallon Capital Management’s Apogee Therapeutics APGE Stock Holding History

Farallon Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-305,000
Closed -$20.3M – 170
2024
Q1 		$20.3M Buy
+305,000
New +$13.3M 0.09% 74

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Farallon Capital Management's APGE Position: Q2 2024 in Review

Farallon Capital Management sold out of Apogee Therapeutics (APGE) in Q2 2024, closing a stake of 305,000 shares — an estimated $20.3M sold.

Farallon Capital Management first reported a position in APGE in Q1 2024 and held it in 1 quarter. The position peaked at $20.3M in Q1 2024. 139 funds tracked by Wall St. Rank hold APGE as of Q2 2024.

  • Farallon Capital Management reported no remaining Apogee Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Farallon Capital Management sold 305,000 Apogee Therapeutics shares in Q2 2024, an estimated $20.3M.
  • Farallon Capital Management first reported a position in Apogee Therapeutics in Q1 2024 and held it in 1 quarter.
  • Farallon Capital Management's Apogee Therapeutics position peaked at $20.3M in Q1 2024.
  • 139 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2024.

Based on Farallon Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.